Italia markets close in 3 hours 6 minutes

Abeona Therapeutics Inc. (0H7R.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
3,2458-0,2342 (-6,73%)
Al 05:03PM GMT. Mercato aperto.
Schermo intero
Chiusura precedente3,4800
Aperto0,0000
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume9.600
Media VolumeN/D
Capitalizzazione906.782
Beta (5 anni mensile)1,21
Rapporto PE (ttm)N/D
EPS (ttm)-0,8080
Prossima data utili14 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Abeona Therapeutics Reports Third Quarter 2022 Financial Results

    Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway into 3Q 2024 NEW YORK and CLEVELAND, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced financial results for the third quarter of 2022. “The positive topline data from the Phase 3 VIITAL study provides strong support for EB-101’s potential and validation of t

  • GlobeNewswire

    Abeona Therapeutics Announces $35 Million Private Placement Financing

    NEW YORK and CLEVELAND, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of its common stock, and, in lieu of shares of common stock, pre-funded warrants exercisable for 543,933 shares of common stock, and accompanying warrants to purchase 7,609,879 shares of its common stock to a group of new and existing institutional investors in a private placement. The offering price fo

  • GlobeNewswire

    Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101

    Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greater magnitude of pain reduction benefit was observed in post-hoc analysis of EB-101 treated wounds with severe baseline pain EB-101 was well-tolerated with no serious treatment-related adverse events, consistent with past clinical experience Plans to submit Biologics License Application (BLA) to U.S.